Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) has an overall financial health rating of B+ with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2026-03-18.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-13 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-11 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-05 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-04 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-01-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
